Synchron Raises $200 Million in Series D Funding
Synchron, a brain-computer interface (BCI) company based in New York, announced a $200 million Series D funding round, increasing its total investment to $345 million.
Funding and Investors
- Round led by Double Point Ventures
- Existing investors participated: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors joined: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
About Synchron’s Stentrode BCI
The Stentrode is a non-surgical, endovascular brain-computer interface designed to enhance mobility, communication, and independence for people with paralysis.
It is implanted through a minimally invasive catheter procedure and connects to the motor cortex via blood vessels, translating brain activity into digital commands.
This hands-free system enables users to control digital devices and has already been implanted in 10 paralysis patients undergoing clinical trials in Australia and the U.S.
Use of Funds and Expansion Plans
Synchron will allocate the new funds to accelerate clinical trials and the commercialization of its BCI technology. The company also aims to grow its operations in New York and San Diego.
In New York, the cognitive AI division focuses on training models using brain data, while the San Diego location hosts the primary engineering hub.
"The Stentrode BCI is a non-surgical endovascular brain-computer interface platform designed to help improve mobility, communication and independence for individuals with paralysis."
Author's Summary: Synchron secured $200 million to enhance its cutting-edge non-surgical brain-computer interface, aiming to accelerate clinical trials and expand its US operations.